Mediolanum International Funds Ltd Makes New Investment in Royalty Pharma plc (NASDAQ:RPRX)

Mediolanum International Funds Ltd bought a new position in shares of Royalty Pharma plc (NASDAQ:RPRX) in the first quarter, Holdings Channel reports. The firm bought 250,507 shares of the biopharmaceutical company’s stock, valued at approximately $7,628,000.

Other institutional investors have also recently bought and sold shares of the company. Torray Investment Partners LLC grew its holdings in Royalty Pharma by 22.6% during the 4th quarter. Torray Investment Partners LLC now owns 505,740 shares of the biopharmaceutical company’s stock worth $14,206,000 after acquiring an additional 93,107 shares during the period. APG Asset Management US Inc. acquired a new stake in Royalty Pharma during the 4th quarter worth $2,100,000. New Century Financial Group LLC acquired a new stake in Royalty Pharma during the 1st quarter worth $1,091,000. Patient Capital Management LLC acquired a new position in shares of Royalty Pharma in the 4th quarter valued at $35,247,000. Finally, S&CO Inc. grew its holdings in shares of Royalty Pharma by 31.0% in the 4th quarter. S&CO Inc. now owns 332,110 shares of the biopharmaceutical company’s stock valued at $9,328,000 after buying an additional 78,500 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Up 0.4 %

NASDAQ RPRX traded up $0.10 on Wednesday, reaching $25.73. The company had a trading volume of 2,247,676 shares, compared to its average volume of 2,714,903. The firm has a market capitalization of $15.37 billion, a price-to-earnings ratio of 19.20, a price-to-earnings-growth ratio of 3.36 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a quick ratio of 12.52 and a current ratio of 12.52. Royalty Pharma plc has a 1-year low of $25.20 and a 1-year high of $31.66. The company’s fifty day moving average is $27.07 and its 200-day moving average is $28.41.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02. Royalty Pharma had a net margin of 35.70% and a return on equity of 22.94%. The firm had revenue of $568.00 million during the quarter, compared to analyst estimates of $671.45 million. During the same period in the prior year, the business earned $1.60 EPS. On average, research analysts forecast that Royalty Pharma plc will post 4.03 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 17th were given a dividend of $0.21 per share. The ex-dividend date was Thursday, May 16th. This represents a $0.84 annualized dividend and a yield of 3.26%. Royalty Pharma’s dividend payout ratio (DPR) is presently 62.69%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. StockNews.com lowered shares of Royalty Pharma from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Bank of America decreased their price target on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a report on Friday, April 12th. Finally, UBS Group lowered shares of Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price target for the company. in a report on Monday, June 3rd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $43.00.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.